Innovent Biologics
2000 Alameda de las Pulgas, suite 120
San Mateo
CA
94403
United States
Website: https://www.innoventbio.com/
126 articles with Innovent Biologics
-
AnHeart and Innovent Announce Interim Data from Phase Ⅱ Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
9/27/2021
AnHeart Therapeutics Co., Ltd together with Innovent Biologics, Inc. announced today interim clinical data from a Phase Ⅱ trial (TRUST) evaluating taletrectinib (AB-106)
-
Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
9/27/2021
Innovent Biologics, Inc. and AnHeart Therapeutics Co., Ltd jointly announced the interim clinical data from a Phase 2 trial evaluating taletrectinib, an investigational next-generation ROS1/NTRK inhibitor in ROS1-positive non-small cell lung cancer.
-
Innovent Announces First Patient Dosed in a Phase 2 Clinical Trial of IBI112 (IL-23 Monoclonal Antibody) in Patients with Moderate-to-severe Plaque Psoriasis
9/23/2021
Innovent Biologics, Group. ("Innovent") (HKEX: 01801), today announced that the first patient with moderate-to-severe plaque psoriasis has been successfully dosed in a Phase 2 clinical trial (clinicaltrials.gov, NCT05003531) of recombinant anti-interleukin 23p19 subunit antibody injection (R & D code: IBI112) in China.
-
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Therapy for Esophageal Squamous Cell Carcinoma (ESCC)
9/22/2021
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), today announced that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for Sintilimab in combination with chemotherapy (cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil) for the first-line treatment of esophageal squamous cell carcinoma (ESCC).
-
Innovent Releases Interim Analysis Results of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma in the Phase 3 ORIENT-15 Study at ESMO Congress 2021
9/18/2021
Innovent Biologics, Inc. announced that the interim analysis results of the Phase 3 ORIENT-15 study evaluating sintilimab in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma were released in an oral presentation at the European Society for Medical Oncology Congress 2021.
-
Innovent Releases Phase 2 Results of Pemigatinib in Chinese Patients with Advanced Cholangiocarcinoma at ESMO Congress 2021
9/16/2021
Innovent Biologics, Inc. ("Innovent", HKEX: 01801), announced that the results of the Phase 2 study in Chinese patients with advanced cholangiocarcinoma were released today at the European Society for Medical Oncology (ESMO) Congress 2021 (E-poster # 50P).
-
Innovent Announces First Patient with Type 2 Diabetes Dosed in a Phase 2 Clinical Trial of IBI362 (a GLP-1R and Glucagon Receptor Dual Agonist) in China
9/7/2021
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), today announced that the first subject with type 2 diabetes has been successfully dosed in a phase 2 clinical trial (clinicaltrials.gov, NCT04965506) of IBI362.
-
Innovent and GenFleet Announce Exclusive Global License Agreement for GFH925 (KRAS G12C Inhibitor)
9/1/2021
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801),, and GenFleet Therapeutics (Shanghai) Inc. ("GenFleet"), today jointly announced that they have entered into an exclusive license agreement for the development and commercialization of GenFleet's lead KRAS G12C candidate.
-
Innovent to Present New Data on Sintilimab and Other Molecules at the European Society for Medical Oncology (ESMO) Congress 2021
8/30/2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, will have multiple scientific data presentations at the European Society for Medical Oncology Virtual Congress 2021, held on September 16-21.
-
Innovent and Bolt Biotherapeutics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs
8/26/2021
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), and Bolt Biotherapeutics, Inc. ("Bolt") (Nasdaq: BOLT), today announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate (ISAC) candidates.
-
Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs
8/26/2021
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), and Innovent Biologics, Inc. (HKEX: 01801), today announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate (ISAC) candidates.
-
Innovent Announced 2021 Interim Results with Total Revenue of RMB 1,941.8 Million and Accelerated Global R&D Footprint
8/25/2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced its interim results for the six months ended June 30, 2021 and the corporate progress.
-
Significant Weight Loss and Multiple Metabolic Benefits: Phase 1b Study Results of IBI362 in Chinese Participants with Overweight or Obesity Published in EClinicalMedicine by the Lancet
8/17/2021
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), today announced that phase 1b study results of IBI362, a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese participants with overweight or obesity have been published in EClinicalMedicine by the Lancet.
-
Innovent Announces Sintilimab in Combination with Chemotherapy Meets the Primary Endpoint of Overall Survival in the Phase 3 ORIENT-16 Study
8/16/2021
Innovent Biologics, Inc. today announced that the sintilimab Phase 3 ORIENT-16 study met its predefined primary endpoint of overall survival (OS).
-
An interim analysis of a Phase III study shows that a combination of Innovent’s sintilimab with chemotherapy significantly improves overall survival compared with placebo in the first-line management of patients with advanced gastric cancer.
-
Innovent Announces IBI306 (anti-PCSK-9 antibody) Meets the Primary Endpoint in a Phase 3 Clinical Study for Chinese Heterozygous Familial Hypercholesterolemia
8/11/2021
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), announces today that the primary endpoint was met in the phase 3 study CREDIT-2 of recombinant fully human anti-PCSK-9 monoclonal antibody (R&D code: IBI306, independently developed by Innovent) for the treatment of Chinese heterozygous familial hypercholesterolemia (HeFH).
-
Innovent Announces the Establishment of the Scientific Advisory Board
8/9/2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announces the establishment of Scientific Advisory Board.
-
Updated Overall Survival Data and Biomarker Results from Sintilimab ORIENT-11 Study in First-Line Nonsquamous Non-Small Cell Lung Cancer Published in the Journal of Thoracic Oncology
8/5/2021
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), and Eli Lilly and Company (NYSE: LLY) today announced new and updated data from the ORIENT-11 study demonstrating a sustained survival benefit of sintilimab in combination with pemetrexed and platinum chemotherapy in the first-line treatment of patients with nonsquamous non-small cell lung cancer.
-
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors
7/26/2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the first patient has been dosed in a Phase 1 study of IBI321, an anti-PD-1/TIGIT bispecific antibody.
-
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI319 (Anti-PD-1/CD137 Bispecific Antibody) in Patients with Advanced Malignant Tumors
7/15/2021
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases announced that the first patient has been dosed in a Phase 1a/1b study of IBI319, an anti-PD-1/CD137 bispecific antibody.